Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
The 19q13.11 microdeletion is characterized by several major features including pre and postnatal growth retardation, slender habitus, severe postnatal feeding difficulties, microcephaly, intellectual deficit with speech disturbance, hypospadias and ectodermal dysplasia presented by scalp aplasia, thin and sparse hair, eyebrows and eyelashes, thin and dry skin and dysplasic nails.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for chromosome 19q13.11 deletion syndrome.
1 publication has been identified in PubMed for chromosome 19q13.11 deletion syndrome. Research spans Review / Meta-Analysis (100%).
Liaqat K (2025). [PMID: 40249340](https://pubmed.ncbi.nlm.nih.gov/40249340/). *Genetic testing and molecular biomarkers*. [Review / Meta-Analysis]
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 1:34 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about chromosome 19q13.11 deletion syndrome